In health care stocks news, Exact Sciences(EXAS) was up 16.6% after the company said Sunday it expects to report revenues between $34.9 million and $35.4 million in Q4, up 142% year-over-year and above the $30.1 million consensus estimate from analysts polled by Capital IQ. For the year the company expects to report revenues between $99.0 million and $99.5 million, up 150% from a year ago and higher than the $94.2 million consensus. The maker of a colon-cancer screening test said 244,000 Cologuard tests were completed in 2016, a 134% increase. Exact said insurance coverage expanded by 67% during 2016.